Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03847974 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003
A Phase 2 study of Hypercholesterolemia, sponsored by LIB Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 3
- Study locations
NCT03847974: Completed Phase 2 study of Hypercholesterolemia, sponsored by LIB Therapeutics.
NCT03847974 is a Phase 2 study of Hypercholesterolemia that has completed, run by LIB Therapeutics. The registered enrollment target is 32 participants, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03847974, a Phase 2 study of Hypercholesterolemia, has completed, sponsored by LIB Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 3
- Study locations
Study Summary
To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)
Primary Outcome
safety and tolerability will be based on the incidence and severity of treatment emergent adverse events
Conditions Studied
Interventions
- DRUG LIB003
Study Locations (3)
Ohio
- Sterling Research Group - Cincinnati
- The Lindner Research Center - Cincinnati
- Metabolic & Atherosclerosis Research Center (MARC) - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-02-14 |
| Est. Completion | 2020-08-31 |
| Phase | Phase 2 |
What the finished NCT03847974 record still lists
NCT03847974 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which LIB003 is the first listed.
NCT03847974 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03847974 about?
NCT03847974 is a clinical study titled "Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003". To assess the longer term safety, tolerability, and LDL C lowering efficacy after 52 weeks of additional treatment with LIB003 with subcutaneous (SC) dosing every 4 weeks (Q4W)
What is the current status of trial NCT03847974?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2019-02-14. Estimated completion is 2020-08-31.
What conditions does trial NCT03847974 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT03847974?
The interventions under investigation include: LIB003 (DRUG).
Who is sponsoring clinical trial NCT03847974?
This trial is sponsored by LIB Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03847974 being conducted?
This trial has 3 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03847974's enrollment target sits among peer trials
32 57th of 62 higher than 6 of 62 other Hypercholesterolemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypercholesterolemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
COMPLETED · Phase 2
-
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
COMPLETED · Phase 2
-
Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)
COMPLETED · Phase 2
-
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
COMPLETED · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI